Natixis Advisors
TEVA icon

Natixis Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Natixis Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.2M Buy
567,585
+1,723
+0.3% +$57.4K 0.02% 552
2026
Q1 		$17M Buy
565,862
+273,557
+94% +$8.8M 0.02% 542
2025
Q4 		$9.12M Buy
292,305
+18,606
+7% +$458K 0.01% 675
2025
Q3 		$5.53M Sell
273,699
-111,516
-29% -$1.96M 0.01% 817
2025
Q2 		$6.46M Buy
385,215
+52,292
+16% +$844K 0.01% 766
2025
Q1 		$5.12M Sell
332,923
-171,611
-34% -$3.07M 0.01% 815
2024
Q4 		$11.1M Buy
504,534
+335,667
+199% +$6.11M 0.02% 617
2024
Q3 		$3.04M Sell
168,867
-32,485
-16% -$569K 0.01% 965
2024
Q2 		$3.27M Buy
201,352
+43,373
+27% +$668K 0.01% 894
2024
Q1 		$2.23M Buy
+157,979
New +$1.99M 0.01% 1005
2017
Q1 		– Sell
-75,515
Closed -$2.74M – 1052
2016
Q4 		$2.74M Sell
75,515
-11,451
-13% -$457K 0.03% 591
2016
Q3 		$4M Sell
86,966
-12,723
-13% -$664K 0.05% 441
2016
Q2 		$5.01M Sell
99,689
-45,231
-31% -$2.41M 0.07% 366
2016
Q1 		$7.75M Buy
144,920
+3,413
+2% +$200K 0.12% 212
2015
Q4 		$9.29M Sell
141,507
-37,398
-21% -$2.31M 0.15% 163
2015
Q3 		$10.1M Sell
178,905
-77,758
-30% -$5.04M 0.18% 135
2015
Q2 		$15.2M Sell
256,663
-3,276
-1% -$202K 0.26% 76
2015
Q1 		$16.2M Buy
259,939
+28,656
+12% +$1.67M 0.28% 63
2014
Q4 		$13.3M Buy
231,283
+63,521
+38% +$3.54M 0.25% 79
2014
Q3 		$9.02M Sell
167,762
-44,257
-21% -$2.34M 0.18% 141
2014
Q2 		$11.1M Buy
212,019
+60,291
+40% +$3.08M 0.16% 184
2014
Q1 		$8.02M Sell
151,728
-13,360
-8% -$617K 0.12% 277
2013
Q4 		$6.62M Sell
165,088
-2,280
-1% -$89.8K 0.11% 309
2013
Q3 		$6.32M Sell
167,368
-9,037
-5% -$353K 0.12% 303
2013
Q2 		$6.92M Buy
+176,405
New +$6.87M 0.14% 254

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Natixis Advisors's TEVA Position: Q2 2026 in Review

Natixis Advisors increased its Teva Pharmaceuticals (TEVA) stake by 0.3% in Q2 2026, buying an estimated $57.4K and bringing the position to 567,585 shares worth $19.2M. The position accounts for 0.02% of the portfolio, ranked #552.

Natixis Advisors first reported a position in TEVA in Q2 2013 and has held it in 25 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Natixis Advisors held 567,585 shares of Teva Pharmaceuticals worth $19.2M as of Q2 2026.
  • Natixis Advisors bought 1,723 Teva Pharmaceuticals shares in Q2 2026, an estimated $57.4K.
  • Teva Pharmaceuticals made up 0.02% of Natixis Advisors's portfolio in Q2 2026, its #552 holding.
  • Natixis Advisors first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 25 quarters since.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.